Title:
併用療法
Document Type and Number:
Japanese Patent JP6592097
Kind Code:
B2
Abstract:
The present invention relates to a combination comprising a proteasome inhibitor and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. In particular, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: a boronate, an epoxyketone, a peptide aldehyde and a β-lactone protease inhibitor; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. More particularly, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: bortezomib, delanzomib, ixazomib, carfilzomib, oprozomib, MG132 and marizomib; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety.
Inventors:
John Bernard March
Ivan Macintosh Clark
Ivan Macintosh Clark
Application Number:
JP2017542354A
Publication Date:
October 16, 2019
Filing Date:
October 27, 2015
Export Citation:
Assignee:
BIG DNA LTD
International Classes:
A61K31/69; A61K31/427; A61K38/12; A61P35/00; A61P35/04; A61P43/00
Domestic Patent References:
| JP2013532628A | ||||
| JP2013506626A |
Foreign References:
| WO2014084378A1 |
Other References:
Chemistry & Biology,2012年,Vol.19, No.1,p.99-115
Attorney, Agent or Firm:
Kenji Sugimura
Mitsutsugu Sugimura
Takao Inoue
Mitsutsugu Sugimura
Takao Inoue